Global Conjugated Monoclonal Antibodies Markets, 2016-2021, 2021-2026F, 2031F by Drugs (Adcetris; Kadcyla) & Technology (Cleavable Linker; Non-cleavable Linker)
20 juin 2022 04h18 HE | Research and Markets
Dublin, June 20, 2022 (GLOBE NEWSWIRE) -- The "Conjugated Monoclonal Antibodies Global Market Report 2022: By Drugs, By Technology, By Application" report has been added to ResearchAndMarkets.com's...
22157.jpg
Global Conjugated Monoclonal Antibodies Markets Report 2021: Focus on Adcetris, Kadcyla, Cleavable Linker, & Non-cleavable Linker - Forecast to 2025 & 2030
10 janv. 2022 05h13 HE | Research and Markets
Dublin, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The "Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
22157.jpg
Global Nuclear Medicine/Radiopharmaceuticals Market (2021 to 2026) - Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities
21 sept. 2021 06h23 HE | Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Global Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha...
TIP_link_300x300.jpg
Radiopharmaceuticals Market ($13.81Bn by 2028) Growth Forecast at 9% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com
24 août 2021 15h06 HE | The Insight Partners
New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Radiopharmaceuticals Market: Key InsightsAccording to our new research study on “Radiopharmaceuticals Market to 2028 – Global Analysis and Forecast – by...
22157.jpg
Global $12.17 Billion Nuclear Medicine Markets to 2028: Beta-emitters, PET, SPECT, Alpha-emitters, Brachytherapy
29 juin 2021 04h13 HE | Research and Markets
Dublin, June 29, 2021 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast,...
22157.jpg
Global Conjugated Monoclonal Antibodies Markets, 2020-2030: COVID-19 Growth, Impacts and Changes
22 déc. 2020 06h08 HE | Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Conjugated Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting
25 juin 2018 16h15 HE | Actinium Pharmaceuticals
Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium  Meeting with Iomab-B and Actimab investigators to be held to provide trial...
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
28 mars 2018 08h00 HE | Actinium Pharmaceuticals
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents  - Actinium to perform preclinical...
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
14 mars 2018 07h30 HE | Actinium Pharmaceuticals
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...
Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting
12 déc. 2017 07h30 HE | Actinium Pharmaceuticals
Higher cell death observed with Actinium-225 labeled daratumumab with up to ten-fold higher potency as compared to naked daratumuambARC of Daratumumab-Actinium-225 labeled with high yield, high...